Drug Trial Radar · NCT03190330
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion
Last checked: Nov 20, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Jun 26, 2019
Primary completion
May 3, 2023
Study completion May 3, 2023
Sponsor
- Lead sponsor
- Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the post-marketing safety of ImbruvicaTM (ibrutinib capsule 140 milligram \[mg\]) under actual conditions of use, and to understand the incidence of adverse events (AEs) (serious and non-serious AEs).
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Mantle-Cell
Interventions
Ibrutinib 420 mgDrug
Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
Ibrutinib 560 mgDrug
Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Day 1 up to 30 days after last dose of study drug (up to 13 months)
- Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Day 1 up to 30 days after last dose of study drug (up to 13 months)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Avron Hospitals Pvt. Ltd
Ahmedabad, India
Post Graduate Institute of Medical Education And Research PGIMER
Chandigarh, India
Basavatarakam Indo-American Hospital
Hyderabad, India
Bhagwan Mahaveer Cancer Hospital & Research Centre
Jaipur, India
Cytecare Hospitals Pvt. Ltd
Karnataka, India
Apollo Multispeciality Hospital Ltd
Kolkata, India
Tata Medical Center
Kolkata, India
Jawaharlal Institute of Postgraduate Medical Education and Research
Puducherry, India
Deenanath Mangeshkar Hospital and Research Centre
Pune, India
Noble Hospital Pvt Ltd
Pune, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.